Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Interest & Investment Income (2016 - 2025)

Ani Pharmaceuticals' Interest & Investment Income history spans 16 years, with the latest figure at -$4.4 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 26.67% year-over-year to -$4.4 million; the TTM value through Dec 2025 reached -$20.1 million, down 13.96%, while the annual FY2025 figure was -$20.1 million, 13.96% down from the prior year.
  • Interest & Investment Income for Q4 2025 was -$4.4 million at Ani Pharmaceuticals, up from -$4.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at -$2.3 million in Q3 2024 and bottomed at -$7.7 million in Q1 2023.
  • The 5-year median for Interest & Investment Income is -$5.5 million (2025), against an average of -$5.2 million.
  • The largest annual shift saw Interest & Investment Income tumbled 190.91% in 2022 before it skyrocketed 63.57% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at -$4.4 million in 2021, then plummeted by 69.05% to -$7.5 million in 2022, then rose by 23.45% to -$5.7 million in 2023, then decreased by 4.68% to -$6.0 million in 2024, then grew by 26.67% to -$4.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Interest & Investment Income are -$4.4 million (Q4 2025), -$4.7 million (Q3 2025), and -$5.4 million (Q2 2025).